StockNewsNow.com Publishes New SNNLive Video Interview with CytoDyn Inc. Discussing Clinical Development

LOS ANGELES, June 22, 2016 /PRNewswire/ -- StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Dr. Nader Pourhassan, President & CEO of CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection, according to the company's website (see here: www.CytoDyn.com). The video interview was recorded on Tuesday, June 7^th, 2016, at the LD Micro Invitational in Bel Air, CA.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

CytoDyn, Inc. – Developing Monoclonal Antibodies for the Treatment and Prevention of HIV Infection

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About CytoDyn 

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection.  The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed phase 2 clinical trials with demonstrated antiviral activity in man and is currently in phase 3.  PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry.  Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5.  Results from seven phase 1 and phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV.  A recent phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy.  CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved. For company description more information on the Company, please visit www.cytodyn.com.

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.

SOURCE StockNewsNow.com

Related Links

http://stocknewsnow.com